LinkedIn · May 2025
Company post highlighting its AI-powered programmable delivery system and the challenges of mRNA delivery.
Cell-specific genetic medicines
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Nuntius Therapeutics is a London-based biotechnology company founded in 2021 that develops cell-specific genetic medicines and mRNA therapies using proprietary dendrimer-lipid nanocarriers, machine learning, and nucleic-acid engineering; its disclosed pipeline targets cancer, lung disease, neurodegenerative disease, and immunotherapy.
Primary product
Proprietary cell-specific mRNA / genetic-medicine delivery platform (dendrimer-lipid nanocarriers)
Founded
2021
Headquarters
London, United Kingdom
Team size
1-10
Industry
Biotechnology Research
Sub-industry
mRNA therapeutics / genetic medicine delivery
Offices
London, United Kingdom
Delaware, United States
Business model
proprietary therapeutics R&D
platform collaboration / partnership
technology-enabled drug discovery
Funding
Stage
Pre-Seed
Total raised
$125K
Latest round
Pre-Seed · Mar 2021
Latest amount
$125K
Mar 2021 · Y Combinator
People & investors
Leadership
Co-Founder & CEO
Co-Founder & CSO
Business Development Lead
Work & culture
Science-driven, patient-outcome-focused startup of scientists, entrepreneurs, and advisors.
Compensation
No public salary bands or compensation policy found.
Product & market
Pricing
Not publicly disclosed; appears partnership- and platform-collaboration driven.
Differentiators
- —Cell-specific delivery beyond the liver
- —Programmable and scalable nanocarriers
- —ML-guided in silico screening of millions of formulations
- —Reportedly outperforming LPXs/LNPs in human-cell delivery
- —Lower-immunogenicity / lower-toxicity delivery approach
Technology
machine learning
random forest models
neural networks
Monte Carlo dropout
dendrimer-lipid nanocarriers
WordPress
Google Workspace
TrackJS
WP Engine
PHP
Nginx
jQuery
imagesLoaded
Competitors
BridgeBio
Alnylam
Alexion
Scale & contact
Latest news
BioCentury · Aug 2024
Notes Nuntius’ emergence from stealth and frames the Taiho deal as the company’s first pharma partnership.
GEN · Aug 2024
Explains the Taiho partnership, describes Nuntius’ delivery tech, and quotes CEO Benita Nagel and CSO Albert Kwok.
Business Wire · Aug 2024
Company press release announcing a collaboration with Taiho Pharmaceutical to use Nuntius’ cell-specific nanocarriers for next-generation mRNA cancer immunotherapies.
Advanced Science / PMC · Jun 2024
Describes Nuntius’ ML-guided screening platform for dendrimer-lipid nanocarriers and the validation of a high-performing candidate.
Jobs and careers at Nuntius Therapeutics
0 jobs at Nuntius Therapeutics
No open positions
Check back later for new openings